Dr. Frederick Alt

I'll research this entity before drafting.

Let me verify Alt's connection to the case and current affiliations.

Note on entity type: "Dr. Frederick Alt" is an individual academic scientist, not a company. He appears in the litigation database as a named defendant in a 1990s trade-secret dispute; there are no corporate product lines, revenue, headcount, or ownership structure to report.

Profile. Frederick W. Alt (Fred Alt) is an American immunologist and geneticist, Charles A. Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School, and Director Emeritus/Co-Director of the Program in Cellular and Molecular Medicine at Boston Children's Hospital. A Howard Hughes Medical Institute Investigator since 1987, he was previously on the faculty at Columbia University (1982–1991), earned a PhD at Stanford (1977) under Robert Schimke, and did postdoctoral work with David Baltimore at MIT. He is a member of the National Academy of Sciences (1994) and National Academy of Medicine (2011), and won the Paul Ehrlich and Ludwig Darmstaedter Prize (2023). Because he is an individual, no revenue band, employee count, or ticker applies.

Work and IP output. Alt's laboratory studies antigen-receptor diversification (V(D)J recombination, IgH class switch recombination), non-homologous end joining and DNA double-strand break repair, genome instability, and the N-myc oncogene. His group developed high-throughput genome-wide translocation sequencing (HTGTS) and engineered mouse models for human antibody discovery. Patent records list him as an inventor on roughly nine issued US patents assigned to Children's Medical Center Corporation, including US 5,583,278 ("Recombination activating gene deficient mouse," 1996) and later anti-PD1 antibody and antibody-optimization filings — institutional/academic patents, not a licensing portfolio.

Litigation posture. The database shows one tracked matter and zero plaintiff suits: Cell Genesys, Inc. v. GenPharm International, Inc. et al. (Santa Clara County Superior Court, No. CV738041, filed 1994), where Alt was a defendant. This is a California state-court trade-secret action, not an Eastern District of Texas patent case. Alt is therefore neither an operating company defending a portfolio nor an NPE; he is an individual swept into private biotech litigation.

Notable context. Cell Genesys alleged that GenPharm misappropriated gene-targeting technology for inactivating mouse antibody genes to create human-antibody mice, and that Alt — a former Cell Genesys consultant — disclosed confidential information to GenPharm. Alt denied the allegations. Cell Genesys dropped the trade-secret claim in January 1997, and in March 1997 the parties settled via a cross-license under which Cell Genesys (with Abgenix, Japan Tobacco, and Xenotech) agreed to pay GenPharm up to $30 million.